Physician profile
Cindy Cunningham
NPI 1447277207
$14,272.40
in general payments reported to CMS, 2019-2025
27 companies · $3,489 in 2025
The $3,489 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,236 · 2022: $2,189 · 2023: $3,697 · 2024: $3,661 · 2025: $3,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,612.64 |
| Education | $234.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,625.80 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,573.93 | 2021-2025 | Invega, Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,535.43 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,353.39 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,346.52 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,142.14 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,024.40 | 2022-2025 | Ingrezza |
| Abbvie INC. | $965.05 | 2021-2025 | |
| Axsome Therapeutics, INC. | $886.27 | 2022-2025 | Auvelity |
| Corium, LLC | $845.33 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $544.84 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $259.32 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $233.25 | 2024-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $165.69 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $159.68 | 2023-2024 | Jornay Pm |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $129.68 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $114.70 | 2022-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $93.67 | 2023-2024 | Quviviq |
| Indivior INC. | $83.53 | 2021-2024 | Perseris |
| Biogen, INC. | $45.33 | 2023 | |
| Avanir Pharmaceuticals, INC. | $43.46 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.09 | 2022 | |
| Noven Therapeutics, LLC | $17.18 | 2024 | Xelstrym |
| Neuronetics, INC. | $16.33 | 2021 | |
| Braeburn INC. | $15.53 | 2023 | Brixadi |
| Collegium Pharmaceutical, INC. | $14.66 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $13.20 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.